# An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

> **NCT01765855** · PHASE1 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Health Volunteers

## Interventions

- **DRUG:** Betrixaban single oral dose

## Key facts

- **NCT ID:** NCT01765855
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01765855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01765855, "An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01765855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*